Genzyme Biosurgery Restructuring Emphasizes R&D Over Hardware
This article was originally published in The Gray Sheet
Executive Summary
Genzyme Biosurgery intends to redirect a portion of its roughly $45 mil. annual R&D budget toward early stage studies of cell therapy for cardiac indications and potential uses of gene therapy during cardiac surgery.
You may also be interested in...
Snowden Pencer Seeks Laparoscopy Partner Following Genzyme Spin-Off
Snowden Pencer, Inc. is seeking a marketing and distribution partner for its line of laparoscopic instruments in the wake of a management-led buyout from Genzyme Biosurgery
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.